Parker Brown

The good news is that a few diabetes drugs now show valid cardioprotective benefits; the bad news is the drugs are unaffordable for many.

The new evidence-based, comprehensive recommendations replace 2012's "piecemeal" effort to guide clinical management.

The annual visit rate to a physician for obesity in 2012 was 49 per 1000 people, according to the latest CDC report.

Surveys show that up to 48% of Americans are actively trying to lose weight. New research finds reliable support in short supply.

British modelling study calculates significant drops in overweight, obesity, and obesity-related diabetes via reducing sugar in beverages alone.

The empagliflozin CV benefit was "astounding" and a first for any diabetes drug, but what does it actually mean?

New study findings are grim, suggesting that fewer than 1% of the obese who work at weight loss will have sustained success.

A large review ties nut consumption to a lower incidence of cancer, but not diabetes.

Underweight means highest risk, say researchers.

The FDA will require labels on prescription testosterone products that disclose a possible increased risk of heart attacks and strokes. A “black box” warning won’t be added.